Anti-Coagulants - France

France

In France, the revenue in the Anti-Coagulants market is predicted to reach €0.75bn in 2024.
The market is expected to exhibit an annual growth rate (CAGR 2024-2029) of 6.55%, leading to a market volume of €1.03bn by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to €15,360.00m in 2024.
France is experiencing a growing demand for novel oral anticoagulants (NOACs) as an alternative to traditional warfarin treatment.

Key regions: Australia, Japan, United States, Germany, Europe

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Coagulants market in France has been experiencing significant growth in recent years.

Customer preferences: One of the key factors driving this growth is the increasing demand for anticoagulant medications in the country. This is due to a number of factors, including an aging population and a rising incidence of cardiovascular diseases. Additionally, there is a growing awareness among patients and healthcare professionals about the benefits of anticoagulant therapy in preventing and treating these conditions.

Trends in the market: One of the major trends in the French anti-coagulants market is the shift towards newer oral anticoagulants (NOACs). These drugs have been shown to be more effective and safer than traditional anticoagulants such as warfarin, and are therefore becoming increasingly popular among patients and healthcare professionals. Another trend is the increasing use of anticoagulants in the prevention of stroke in patients with atrial fibrillation.

Local special circumstances: France has a well-established healthcare system that provides universal access to healthcare for all citizens. This has helped to drive demand for anticoagulant medications in the country, as patients are able to access these drugs through their healthcare providers. Additionally, there is a strong pharmaceutical industry in France, which has helped to support the development and marketing of new anticoagulant drugs.

Underlying macroeconomic factors: The French economy has been growing steadily in recent years, which has helped to support the growth of the anticoagulants market. Additionally, the country has a large and aging population, which is driving demand for healthcare services and medications. However, there are also challenges facing the French healthcare system, including rising healthcare costs and an increasing burden of chronic diseases. These factors could impact the growth of the anticoagulants market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.